

Further reading

1. De Maio M, Rzany B. *Injectable Fillers in Aesthetic Medicine*. Springer Berlin Heidelberg. 2006 ISBN 3-540-23941-3. [[Google Scholar](#)]
2. Hirsch RJ, Brody HJ, Carruthers JDA. Hyaluronidase in the office: a necessity for every dermasurgeon that injects HA. *J Cosmet and Laser Ther*. 2007;9:182–185. [[PubMed](#)] [[Google Scholar](#)]
3. Cavallini M, Gazzola R, Metalla M, Vaienti L. The role of hyaluronidase in the retreatment of complications from HA dermal fillers. *Aesthet Surg J*. 2013 Nov;33(8):1167–1174. [[PubMed](#)] [[Google Scholar](#)]
4. Buhren BA, Schrupf H, Hoff NP, et al. Hyaluronidase: from clinical applications to molecular and cellular mechanisms. *Eur J Med Res*. 2016;21:5. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
5. British National Formulary, 10.3 Drugs for the treatment of soft-tissue disorders and topical pain relief, 10.3.1 Enzymes, Hyaluronidase
6. Kim DW, Yoon ES, Ji YH, Park SH, Lee BI, Dhong ES. Vascular complications of HA fillers and the role of hyaluronidase in management. *J Plast Reconstr Aesthet Surg*. 2011;64:1590–1595. [[PubMed](#)] [[Google Scholar](#)]
7. DeLorenzi C. Complications of injectable fillers, part I. *Aesthet Surg J*. 2013;33:561–75. [[PubMed](#)] [[Google Scholar](#)]
8. Meyer K. Hyaluronidases. In: Boyer PD, editor. *The Enzymes*. New York, NY: Academic Press; 1971. pp. 307–320. [[Google Scholar](#)]
9. Andre P, Levy PM. Hyaluronidase offers an efficacious treatment for inaesthetic HA overcorrection. *J Cosmet Dermatol*. 2007;6(4):159–162. [[PubMed](#)] [[Google Scholar](#)]
10. Quezada-Gaón N, Wortsman X. Ultrasound-guided hyaluronidase injection in cosmetic complications. *J Eur Acad Dermatol Venereol*. 2016;30(10):e39–e40. [[PubMed](#)] [[Google Scholar](#)]
11. Bailey SH, Fagien S, Rohrich RJ. Changing role of hyaluronidase in plastic surgery. *Plast Reconstr Surg*. 2014;133(2):127e–132e. [[PubMed](#)] [[Google Scholar](#)]
12. Papakonstantinou E, Roth M, Karakiulakis G. HA: A key molecule in skin aging. *Dermatoendocrinol*. 2012;4(3):253–258. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
13. King M. Management of necrosis. Aesthetic Complications Expert (ACE) Group guidelines. Oct, 2016. [Accessed 16 May 2018]. <http://acegroup.online/wp-content/uploads/2016/01/Necrosis-v1.4.pdf>
14. DeLorenzi C. Complications of injectable fillers, part 2: vascular complications. *Aesthet Surg J*. 2014;34(4):584–600. [[PubMed](#)] [[Google Scholar](#)]
15. Cavallini M, Gazzola R, Metalla M, Vaienti L. The role of hyaluronidase in the treatment of complications from HA dermal fillers. *Aesthet Surg J*. 2013;33(8):1167–1174. [[PubMed](#)] [[Google Scholar](#)]
16. Sun ZS, Zhu GZ, Wang HB, et al. Clinical outcomes of impending nasal skin necrosis related to nose and nasolabial fold augmentation with HA fillers. *Plast Reconstr Surg*. 2015;136(4):434e–441e. [[PubMed](#)] [[Google Scholar](#)]
17. Kim DW, Yoon ES, Ji YH, Park SH, Lee BI, Dhong ES. Vascular complications of HA fillers and the role of hyaluronidase in management. *J Plast Reconstr Aesthet Surg*. 2011;64(12):1590–1595. [[PubMed](#)] [[Google Scholar](#)]
18. Walker L, King M. Visual loss secondary to cosmetic filler injection. Aesthetic Complications Expert (ACE) Group guidelines. Oct, 2017. [Accessed 16 May 2018]. <http://acegroup.online/wp-content/uploads/2016/01/ACE-Group-Blindness-v2.5.pdf>

19. Carruthers JD, Fagien S, Rohrich RJ, Weinkle S, Carruthers A. Blindness caused by cosmetic filler injection: a review of cause and therapy. *Plast Reconstr Surg.* 2014;134(6):1197–1201. [[PubMed](#)] [[Google Scholar](#)]
20. King M. Management of Tyndall effect. *Aesthetic Complications Expert (ACE) Group guidelines.* Jun, 2016. [Accessed 16 May 2018]. <http://acegroup.online/wp-content/uploads/2016/01/Tyndalls-v1.2.pdf>
21. United Kingdom Medicines and Healthcare Products Regulatory Agency. Hyaluronidase 1500 I.U. powder for solution for injection / infusion. Summary of product characteristics (SPC) Dec 12, 2014. [Accessed 16 May 2018]. <http://www.mhra.gov.uk/home/groups/spcpil/documents/spcpil/con1523594013492.pdf>
22. Rzany B, Becker-Wegerich P, Bachmann F, Erdmann R, Wollina U. Hyaluronidase in the correction of HA-based fillers: a review and a recommendation for use. *J Cosmet Dermatol.* 2009;8(4):317–323. [[PubMed](#)] [[Google Scholar](#)]
23. Juhász MLW, Levin MK, Marmur ES. The kinetics of reversible HA filler injection treated with hyaluronidase. *Dermatol Surg.* 2017;43:841–847. [[PubMed](#)] [[Google Scholar](#)]
24. Rao V, Chi S, Woodward J. Reversing facial fillers: interactions between hyaluronidase and commercially available hyaluronic-acid based fillers. *J Drugs Dermatol.* 2014;13(9):1053–1056. [[PubMed](#)] [[Google Scholar](#)]
25. Woodward J, Khan T, Martin J. Facial filler complications. *Facial Plast Surg Clin North Am.* 2015;23(4):447–458. [[PubMed](#)] [[Google Scholar](#)]
26. Hirsch RJ, Cohen JL, Carruthers JD. Successful management of an unusual presentation of impending necrosis following a HA injection embolus and a proposed algorithm for management with hyaluronidase. *Dermatol Surg.* 2007;33(3):357–360. [[PubMed](#)] [[Google Scholar](#)]
27. Cox SE. Clinical experience with filler complications. *Dermatol Surg.* 2009;35(suppl 2):1661–1666. [[PubMed](#)] [[Google Scholar](#)]
28. Menon H, Thomas M, D'silva J. Low dose of hyaluronidase to treat over correction by HA filler-a case report. *J Plast Reconstr Aesthet Surg.* 2010;63(4):e416–e417. [[PubMed](#)] [[Google Scholar](#)]
29. Menon H, Thomas M, D'silva J. Low dose of hyaluronidase to treat over correction of HA filler-a case report. *J Plast Reconstr Aesthetic Surg.* 2010;63:416–417. [[PubMed](#)] [[Google Scholar](#)]
30. Van Dyke S, Hays GP, Caglia AE, Caglia M. Severe acute local reactions to a HA-derived dermal filler. *J Clin Aesthetic Dermatol.* 2010;3(5):32–35. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
31. DeLorenzi C. New high dose pulsed hyaluronidase protocol for HA filler vascular adverse events. *Aesthet Surg J.* 2017. doi: 10.1093/asj/sjw251. [[PubMed](#)]
32. Landau M. Hyaluronidase caveats in treating filler complications. *Dermatol Surg.* 2015;41(Suppl 1):S347–S353.2. [[PubMed](#)] [[Google Scholar](#)]
33. DeLorenzi C. Transarterial degradation of HA filler by hyaluronidase. *Dermatol Surg.* 2014;40(8):832–841. [[PubMed](#)] [[Google Scholar](#)]
34. Cohen JL, Biesman BS, Dayan SH, et al. Treatment of HA filler-induced impending necrosis with hyaluronidase: consensus recommendations. *Aesthet Surg J.* 2015;35(7):844–849. [[PubMed](#)] [[Google Scholar](#)]
35. Andre P, Fléchet ML. Angioedema after ovine hyaluronidase injection for treating HA overcorrection. *J Cosmet Dermatol.* 2008;7(2):136–138. [[PubMed](#)] [[Google Scholar](#)]
36. Flynn T. Hyaluronidase. *Body Language, Issue 44*

37. Vartanian JA, Frankel AS, Rubin MG. Injected hyaluronidase reduces restylane-mediated cutaneous augmentation. *Arch Facial Plast Surg*. 2005;7:231–237. [[PubMed](#)] [[Google Scholar](#)]
38. Rzany B, Becker-Wegerich P, Bachmann F, Erdmann R, Wollina U. Hyaluronidase in the correction of HA-based fillers: a review and a recommendation for use. *J Cosmet Dermatol*. 2009;8(4):317–323. [[PubMed](#)] [[Google Scholar](#)]
39. Yocum RC, Kennard D, Heiner LS. Assessment and implication of the allergic sensitivity to a single dose of recombinant human hyaluronidase injection: a double-blind, placebo-controlled clinical trial. *J Infus Nurs*. 2007;30(5):293–299. [[PubMed](#)] [[Google Scholar](#)]
40. Dunn AL, Heavner JE, Racz G, Day M. Hyaluronidase: A review of approved formulations, indications and off-label use in chronic pain management. *Expert Opin Biol Ther*. 2010;10(1):127–131. [[PubMed](#)] [[Google Scholar](#)]
41. Cohen BE, Bashey S, Wysong A. The use of hyaluronidase in cosmetic dermatology: a review of the literature. *J Clin Investigat Dermatol*. 2015;3(2):7. [[Google Scholar](#)]
42. Lee A, Grummer SE, Kriegel D, Marmur E. Hyaluronidase. *Dermatol Surg*. 2010;36(7):1071–1077. [[PubMed](#)] [[Google Scholar](#)]

43. Szepefalusi Z, Nentwich I, Dobner M, Pillwein K, Urbanek R. IgE-mediated allergic reaction to hyaluronidase in paediatric oncological patients. *Eur J Pediatr*. 1997;156(3):199–203. [[PubMed](#)] [[Google Scholar](#)]